For the quarter ended March 2023, GoodRx Holdings, Inc. (GDRX - Free Report) reported revenue of $183.99 million, down 9.5% over the same period last year. EPS came in at $0.07, compared to $0.10 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $181.87 million, representing a surprise of +1.16%. The company delivered an EPS surprise of +16.67%, with the consensus EPS estimate being $0.06.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how GoodRx Holdings, Inc. performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Prescription transactions revenue: $134.90 million versus $134.11 million estimated by seven analysts on average.
- Other Revenue: $4.50 million versus the seven-analyst average estimate of $10.29 million.
- Subscription Revenue: $24.10 million versus $23.57 million estimated by seven analysts on average.
- Pharma Manufacturer Solutions Revenue: $20.40 million versus $20.04 million estimated by six analysts on average.
View all Key Company Metrics for GoodRx Holdings, Inc. here>>>Shares of GoodRx Holdings, Inc. have returned -19.3% over the past month versus the Zacks S&P 500 composite's +0.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Top 5 ChatGPT Stocks Revealed
Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.”
Download Free ChatGPT Stock Report Right Now >>
For the quarter ended March 2023, GoodRx Holdings, Inc. (GDRX - Free Report) reported revenue of $183.99 million, down 9.5% over the same period last year. EPS came in at $0.07, compared to $0.10 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $181.87 million, representing a surprise of +1.16%. The company delivered an EPS surprise of +16.67%, with the consensus EPS estimate being $0.06.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how GoodRx Holdings, Inc. performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Prescription transactions revenue: $134.90 million versus $134.11 million estimated by seven analysts on average.
- Other Revenue: $4.50 million versus the seven-analyst average estimate of $10.29 million.
- Subscription Revenue: $24.10 million versus $23.57 million estimated by seven analysts on average.
- Pharma Manufacturer Solutions Revenue: $20.40 million versus $20.04 million estimated by six analysts on average.
View all Key Company Metrics for GoodRx Holdings, Inc. here>>>Shares of GoodRx Holdings, Inc. have returned -19.3% over the past month versus the Zacks S&P 500 composite's +0.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Top 5 ChatGPT Stocks Revealed
Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.”
Download Free ChatGPT Stock Report Right Now >>
Get the latest research report on GDRX - FREE